Cellules souches

<p>CHIR 98024: strong GSK-3α/β blocker, IC50 0.65/0.58 nM, selective over Cdc2/ERK2.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse CC17. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse CC17. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse CC17, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse CC17 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat Cys-C. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat Cys-C. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat Cys-C, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse TNC. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse TNC. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse TNC, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse TNC in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.Cost-effective and quality-assured.</p>

<p>VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.Cost-effective and quality-assured.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Cys-C, and the Human Cys-C standard plate wells that pre-coated using protein-related techniques are provided separately. Standard/Sample Diluent Buffer or samples are added to the appropriate microtiter plate wells ,then added a HRP-conjugated antibody specific to Human Cys-C. After TMB substrate solution is added, only those wells that contain Human Cys-C and HRP-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Cys-C in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>Potent oral TEAD-YAP/TAZ inhibitor-2 with 3 nM EC50; exhibits anti-proliferative and antitumor effects.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse GDF10. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse GDF10. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse GDF10, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse GDF10 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.</p>

<p>The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human ASPP1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human ASPP1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human ASPP1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human ASPP1 in the samples is then determined by comparing the OD of the samples to the standard curve.</p>

<p>Metelimumab (CAT-192) is a humanised monoclonal antibody targeting TGFβ1, which can be used to study diffuse systemic sclerosis (d-SSc).</p>

<p>Trevogrumab is a human monoclonal antibody that inhibits myostatin (GDF8) to promote muscle growth, and is under research for treating age-related muscle loss (sarcopenia).</p>

<p>Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32</p>

<p>Nisevokitug (anti-TGF-β mAb) neutralizes TGF-β and is being studied for its ability to modulate the immunosuppressive tumor microenvironment.</p>

<p>1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, &gt;100-fold selectivity over CDK1/cyclin B and CDK5/p25.</p>

<p>CK2-IN-4 is a protein kinase (CK2) inhibitor with an IC50 value of 8.6 µM.</p>

<p>CAY10746 selectively inhibits ROCK I/II with IC50s: 0.014/0.003 μM, useful for diabetic retinopathy research.</p>

<p>Aloisine B (AloisineB) inhibited cyclin-dependent kinase and glycogen synthase kinase with IC50 values of 0.85 µM and 0.75 µM, respectively.</p>

<p>SIS3 free base is a potent and selective Smad3 phosphorylation inhibitor. SIS3 free base inhibits the myofibroblast differentiation of fibroblasts by TGF-β1.</p>

<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>

<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>

<p>SB-772077B dihydrochloride is an aminofurazan-based Rho kinase inhibitor (IC50s: 5.6 nM and 6 nM toward ROCK1 and ROCK2, respectively).</p>

<p>Aβ42-IN-2 is a γ-secretase modulator. Aβ42-IN-2 has an IC 50 of 6.5 nM for Αβ 42. Aβ42-IN-2 can be used for the Alzheimer's disease research[1].</p>

<p>VT103, an oral TEAD1 palmitoylation inhibitor, shows promise against various cancers by disrupting YAP/TAZ-TEAD interactions.</p>

<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>

<p>inS3-54-A26 is an inhibitor of the DNA-binding domain of STAT3. inS3-54-A26 suppresses tumor growth, metastasis and the gene expression of STAT3.</p>

<p>Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP).</p>

<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>

<p>3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in</p>

<p>CJJ300 is a TGF-β inhibitor disrupting TGF-β-TβR complex formation, with an IC50 of 5.3 μM, and halts cell migration.</p>

<p>BRD0209 is a highly selective and potent GSK3 inhibitor.</p>

<p>TGFβRI-IN-1 is an oral active and selective inhibitor of TGFβ receptor type I (TGFβRI) kinase(IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII,</p>

<p>JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).</p>

<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>

<p>β-catenin/CBP-IN-1 is a potent and selective inhibitor of CBP/β-catenin</p>

<p>AF-2112, a TEAD inhibitor derived from Flufenamic acid, significantly diminishes the expression of CTGF, Cyr61, Axl, and NF2.</p>

<p>TEAD-IN-2 is a potent and bifunctional TEAD inhibitor to induce TEAD protein degradation via the ubiquitination pathway, with anticancer potential.</p>

<p>gamma-secretase modulator 1 is a modulator of γ secretase and can be used in studies about the treatment of Alzheimer's disease.</p>

<p>JA310 is a highly selective inhibitor of the MST3 kinase, demonstrating significant cellular potency with an EC50 value of 106 nM [1].</p>

<p>GSK3-IN-2 is a potent GSK3 inhibitor for the treatment of diabetes and neurodegenerative diseases.</p>

<p>Wnt pathway activator 2 is a potent Wnt activator with an IC50 of 13 nM.</p>

<p>GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.GSK-3β</p>

<p>ELN318463 racemate (ELN 318463 racemate) is the racemate of ELN318463 which is an amyloid precursor protein (APP) selective γ-secretase inhibitor.</p>

<p>JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50</p>

<p>H-1152 is a potent, specific, ATP-competitive, and cell permeable ROCK inhibitor (Ki = 1.6 nM).</p>

<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>

<p>PIMPC, a compound endowed with antioxidant and metal-chelating properties, acts as a novel inhibitor of glycogen synthase kinase 3 (GSK-3), and exhibits</p>

<p>CK2α-IN-1 is a selective non-ATP-competitive CK2α inhibitor with an IC50 of 7.0 µM and a Ki of 1.6 µM.CK2α-IN-1 exhibits potential anticancer activity and can</p>

<p>JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].</p>

<p>SR-1277 is a potent, highly selective and ATP-competitive CK1δ/ε inhibitor, regulating Wee1 activity at the G2/M cell-cycle interface, and antiproliferative.</p>

<p>TEAD-IN-6 (Example 11-1) is a TEAD modulator that inhibits the YAP1/TAZ-TEAD interaction, and has applications in cancer research [1].</p>

<p>PI-828 (LY 294002), a PI3K inhibitor, researches PI3K function and aids stem cell differentiation into mesoderm.</p>

<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>

<p>GSK-3 InhibitorXIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.</p>

<p>GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM.</p>

<p>AS 1892802, a ROCK inhibitor: IC50 - 52nM (hROCK2), 57nM (rROCK2), 122nM (hROCK1). Fast antinociceptive effect similar to Tramadol, Diclofenac.</p>

<p>IHMT-MST1-58 is a STE20-like protein 1 kinase (MST1) inhibitor (IC50:23 nM) with high efficiency, selectivity and oral activity.</p>

<p>FzM1.8: allosteric FZD4 agonist, pEC50=6.4; boosts TCF/LEF, activates WNT/β-catenin with no WNT needed.</p>

<p>ABC1183, an oral diaminothiazole, inhibits GSK3α/β, CDK9, hinders cancer cell growth, induces G2/M arrest, and modulates phosphorylation.</p>

<p>GSK-3β inhibitor 2 (5-Thiazolecarboxamide,2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-) is a BBB-crossing and selective inhibitor of GSK-3β (IC50</p>

<p>LM-41 is a TEAD binding agent with potential anticancer activity for the study of breast cancer.</p>

<p>BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor.</p>

<p>BMS-863233 HCl is an ATP-competitive Cdc7 inhibitor (IC50: 3.4 nM) that is potent and selective.BMS-863233 HCl inhibited CK2 and PIM1 with IC50 values of 215</p>

<p>SJ000063181 activates BMP signaling (EC50 ≤1μM), usable as probe in zebrafish embryos.</p>

<p>Rhodblock 6 is a Rho kinase inhibitor, blocking phosphorylated MRLC localization by targeting ROCK activity.</p>

<p>FzM1, a negative allosteric modulator (NAM) of the Frizzled receptor FZD4, diminishes WNT5A-dependent WNT responsive element (WRE) activity (log EC50inh=−6.2)</p>

<p>Casein kinase 1δ-IN-1 (WAY-643895) is an inhibitor of casein kinase 1δ (CK1δ), which inhibits CK1δ.</p>

<p>TT-10 (TAZ-K) activates YAP-TEAD; useful in heart disease with cardiomyocyte loss research.</p>

<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50&lt;500 nM).</p>

<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>

<p>MSC-4106, an oral YAP/TAZ-TEAD inhibitor, blocks TEAD1/3 auto-palmitoylation and suppresses NCI-H226 tumors.</p>

<p>DIF-3 activates GSK-3β, degrades cyclin D1/c-Myc, and inhibits Wnt/β-catenin in DLD-1 cells, curbing HeLa cell proliferation.</p>

<p>CID-5056270 has anticancer activity and can inhibit lung cancer, anal cancer, bladder cancer, cervical cancer, vulvar cancer, penile cancer, Burkitt's lymphoma</p>

<p>EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.</p>

<p>CRT0066854 HCl inhibits atypical PKCs; IC50: PKCι 132 nM, PKCζ 639 nM, ROCK-II 620 nM.</p>

<p>Rho-Kinase-IN-1: ROCK inhibitor, Ki of 30.5 nM (ROCK1) &amp; 3.9 nM (ROCK2), used in research for diseases linked to cell overgrowth and inflammation.</p>

<p>Miclxin (DS37262926) is a novel MIC60 inhibitor that induces apoptosis through mitochondrial stress in mutant tumor cells via β-catenin.Miclxin is a potent</p>

<p>ARN25068 inhibits GSK-3β, FYN, DYRK1A kinases; acts in sub-micromolar range; combats tau hyperphosphorylation.</p>

<p>Wnt/β-catenin agonist 4 is an agonist of Wnt that activates Wnt/β-catenin signaling and directs signaling.</p>

<p>LEQ506 is a Smo inhibitor with IC50s of 2 nM and 4 nM for hSmo and mSmo, respectively.</p>

<p>ROCK-IN-8 (Example 4), a ROCK inhibitor, exhibits anti-inflammatory properties and is suitable for respiratory and gastro-intestinal disease research,</p>

<p>Casein kinase 1δ-IN-10 is an inhibitor of casein kinase 1δ (CK1δ).</p>

<p>inS3-54A18 is an effective inhibitor of STAT3. inS3-54A18 has anticancer effects.</p>

<p>BMS-983970 is an oral inhibitor of pan-Notch, and for the treatment of multiplecancers.</p>

<p>ROCK2-IN-6 hydrochloride (Comp A)为一种选择性ROCK2抑制剂，适用于研究ROCK介导的疾病、自身免疫性病症与炎症。</p>

<p>BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705.</p>

<p>Casein kinase 1δ-IN-5 is a potent and selective CK-1δ inhibitor, exhibiting an IC50 of 47 nM, and demonstrates neuroprotective and anti-inflammatory effects in</p>

<p>STAT6-IN-3 (Compound 18a) serves as an inhibitor of STAT6 with an IC50 value of 44 nM, specifically targeting the Src Homology 2 (SH2) domain.</p>

<p>Stafib-2 is a potent and selective inhibitor of the transcription factor STAT5b.Stafib-2 inhibits STAT5b and STAT5a with IC50 values of 82 nM and 1.7 μM,</p>

<p>JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.</p>

<p>Antitumor Agent-73, derived from Diosgenin, blocks STAT3 and activates Pdia3, showing strong cancer cell line efficacy.</p>

<p>JW 67 is an inhibitor of canonical Wnt pathway signaling.</p>

<p>YAP-TEAD-IN-2 (compound 6) serves as a potent inhibitor of the YAP-TEAD protein-protein interaction (PPI), demonstrating an inhibitory concentration 50 (IC50)</p>

<p>ROCK2-IN-2 is a selective inhibitor of ROCK2 (IC50 of &lt;1 μM).</p>

<p>Myristoyl Tetrapeptide-12 activates SMAD2 and facilitates the association of SMAD3 with DNA, promoting eyelash hair growth [1] [2].</p>

<p>A 1070722: potent GSK-3 inhibitor, Ki = 0.6 nM for both α/β isoforms, crosses BBB, potential brain GSK-3 PET radiotracer.</p>

<p>STAT3-IN-20 (Compound 40), with an IC50 of 0.65 μM, is a selective inhibitor targeting the SH2 domain of STAT3, thereby impeding its phosphorylation, nuclear</p>

<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>

<p>Casein kinase II inhibitor IV is an effective small molecule inducer, which can be used to induce epidermal keratinocyte differentiation.</p>